Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Publication | Closed Access

DOI

1.2K

Citations

References

2019

Year

Peter Schmid, Hope S. Rugo, Sylvia Adams, Andreas Schneeweiß, Carlos H. Barrios, Hiroji Iwata, Véronique Dièras, Volkmar Henschel, Luciana Molinero, Vidya Maiya,

The Lancet Oncology

Breast OncologyOncologyMedicineBreast CancerPharmacotherapyFirst-line TreatmentCancer TreatmentPharmacologyMolecular OncologyEfficacy Results